deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 10-arm NCT03767348

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (IGNYTE)

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]

Sponsor: Bristol-Myers Squibb

Conditions Cutaneous Melanoma Microsatellite Instability-High (MSI-H) Non-Small Cell Lung Cancer (NSCLC) Non-melanoma Skin Cancer (NMSC)
Interventions RP1 nivolumab
Updated 28 times since 2019 Last updated: Feb 12, 2026 Started: Sep 20, 2017 Primary completion: Jun 30, 2028 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03767348, this PHASE2 trial focuses on Cutaneous Melanoma and Microsatellite Instability-High (MSI-H) and remains ongoing. Sponsored by Bristol-Myers Squibb, it has been updated 28 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Nov 2020 · 5 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Jun 2023 · 5 months · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – present · 4 months · monthly snapshot

Change History

28 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2026 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2025 — Jan 2026 [monthly]

    Recruiting PHASE2

  4. Feb 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

  5. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE2

▶ Show 23 earlier versions

  1. Oct 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  2. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Sep 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. Jun 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  6. Jan 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  7. Nov 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  8. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  9. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  10. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  11. Feb 2022 — May 2022 [monthly]

    Recruiting PHASE2

  12. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  13. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  14. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

    Phase: PHASE1_PHASE2 → PHASE2

  15. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  16. Jun 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  17. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  18. Jan 2020 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  19. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE1_PHASE2

  20. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

  21. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  22. Mar 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  23. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Replimune Inc.
Data source: Replimune Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bebington, United Kingdom , Berlin, Germany , Besançon, France , Birmingham, United States , Bordeaux, France , Charleston, United States , Cincinnati, United States , Dijon, France , Durham, United States and 37 more locations